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Hepatitis C virus-induced hepatocarcinogenesisq
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4Department of Medicine II, University Freiburg, Freiburg, GermanyAlthough there is strong evidence that hepatitis C virus (HCV) is one of the leading causes of hepatocellular carcinoma
(HCC), there is still much to understand regarding the mechanism of HCV-induced transformation. While liver ﬁbrosis
resulting from long-lasting chronic inﬂammation and liver regeneration resulting from immune-mediated cell death are
likely factors that contribute to the development of HCC, the direct role of HCV proteins remains to be determined.
In vitro studies have shown that HCV expression may interfere with cellular functions that are important for cell diﬀer-
entiation and cell growth. However, most studies were performed in artiﬁcial models which can only give clues for potential
mechanisms that need to be conﬁrmed in more relevant models. Furthermore, the diﬃculty to identify HCV proteins and
infected liver cells in patients, contributes to the complexity of our current understanding. For these reasons, there is cur-
rently very little experimental evidence for a direct oncogenic role of HCV. Further studies are warranted to clarify these
issues.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Chronic hepatitis C virus (HCV) infection is charac-
terized by inﬂammatory lesions in the liver, often
accompanied by intrahepatic lipid accumulation (steato-
sis) and progressive ﬁbrosis of variable degrees, and
long-term progression to cirrhosis and hepatocellular0168-8278/$36.00  2009 European Association for the Study of the Liver.
doi:10.1016/j.jhep.2009.05.008
Associate Editor: K. Koike
q The authors who have taken part in this study declared that they do
not have anything to disclose regarding funding from industry or
conﬂict of interest with respect to this manuscript.
* Corresponding author. Tel.: +33 437497410; fax: +33 437497419.
E-mail address: fabien.zoulim@inserm.fr (F. Zoulim).
Abbreviations: HCV, hepatitis C virus; HCC, hepatocellular car-
cinoma; NCR, non-coding region; NS, non-structural; vLDL, very low
density lipoproteins; B-NHL, B-cell non-Hodgkin lymphoma; MAPK,
mitogen-activated protein kinase; NAFLD, non-alcoholic fatty liver
disease; NASH, non-alcoholic steatohepatitis; IR, insulin resistance;
IRS, insulin resistance substrate; ER, endoplasmic reticulum; ROS,
reactive oxygen species.carcinoma (HCC) [1,2]. HCC incidence has increased
sharply over recent decades and has been attributed to
chronic HCV infection. Chronic HCV infection, there-
fore, is a major risk factor for HCC development.
Indeed, each year, 4-5% of patients with chronic hepati-
tis C develop HCC. Serological markers of HCV infec-
tion in patients with HCC range from 27% up to 80%,
and HCV infection increases the risk for HCC develop-
ment by an estimated 17-fold compared to healthy indi-
viduals [3–6] (Table 1). Host, environmental and viral
factors appear to play an important role in determining
progression of chronic hepatitis C to liver cirrhosis and
HCC, a process that frequently takes several decades
(Fig. 1). The molecular mechanisms underlying HCC
development remain ill-deﬁned. So far, it has not been
possible to correlate speciﬁc changes in gene expression
patterns with HCC development. HCV does not inte-
grate into its host genome and has a predominantly
cytoplasmic life cycle [7]. Hepatocarcinogenesis, there-
fore, must involve several indirect mechanisms includingPublished by Elsevier B.V. All rights reserved.
Table 1
Association between HCV infection and human malignancies.
Malignancy Fold risk increase Reference
Hepatocellular carcinoma 3- to 17-fold [3–6]
B-cell non-Hodgkin lymphoma 2- to 10-fold [35–37]
Intrahepatic cholangiocarcinoma 2- to 6-fold [39–41]
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ﬁbrosis and oxidative stress and their pathological con-
sequences. In addition, several HCV proteins have been
shown to have direct oncogenic eﬀects and to upregulate
mitogenic processes. Increased cell proliferation in a set-
ting of oxidative stress leads to accumulation of DNA
damage and is thought to compromise gene and chro-
mosome stability and to form the genomic basis for
the malignant transformation of the hepatocyte. Here,
we review the epidemiology of HCV-induced HCC
and the potential underlying molecular mechanisms.2. HCV infection: the virus and the disease
In the 1970s and 1980s, serological analyses devel-
oped for the detection of hepatitis A virus (HAV) and
hepatitis B virus (HBV) infection, respectively, indicated
that the majority of transfusion-transmitted hepatitis
was not caused by either HAV or HBV and was there-
fore termed non-A, non-B hepatitis (NANBH). The eti-
ological agent of NANBH was discovered in 1989 and
was termed HCV. Based on its structural and functional
organization HCV was classiﬁed into the family of theFig. 1. HCV-induced hepatocarcinogenesis.Flaviviridae, where it forms its own genus Hepacivirus’
[8]. The HCV genome is a single-stranded, positive sense
RNA of approx. 9600 nt in length [9] with genetic heter-
ogeneity, resulting in its classiﬁcation into six diﬀerent
genotypes. The HCV genome contains short non-coding
regions (NCR) at each end. The coding sequence is
translated into a polyprotein that is processed by viral
and cellular proteases. The 50-region of the genome
encodes the structural proteins, including the nucleocap-
sid protein (core) and two envelope glycoproteins (E1
and E2) that form the viral particle, followed by a num-
ber of non-structural (NS) proteins, designated NS2 to
NS5B in the 30-region.
HCV is considered hepatotropic, and only man and
chimpanzees are susceptible to HCV infection and dis-
ease [10,11]. While HCV RNA has been unequivocally
detected in hepatocytes in liver biopsies from chronically
infected patients and chimpanzees, the HCV genome
seems to replicate also in cells of lymphoid origin and
dendritic cells [12–14]. Circulating HCV particles have
a diameter of 35–50 nm and are frequently associated
with either immune globulins or very low density lipo-
proteins (vLDL) [15]. Indeed, the vLDL biosynthesis
machinery plays a pivotal role in the life cycle of HCV
[15–17].
Risk factors for HCV transmission include transfu-
sion of blood and blood products, transplantation of
solid organs from infected donors, injecting drug use,
unsafe therapeutic injections and occupational exposure
to blood [18]. The rate of transmission after a needle-
stick injury from HCV positive blood ranges from 0 to
10% in most studies. The rate of perinatal HCV trans-
mission is 4–7% and occurs only when HCV RNA is
detectable in maternal serum at delivery. Importantly,
coinfection with HIV increases the rate of perinatal
transmission 4- to 5-fold [18].
Persistence of HCV infection occurs in the majority
of HCV-infected individuals. Indeed, acute hepatitis C
resolves spontaneously only in about 10–40% of cases
[19,20]. Chronic hepatitis C is characterized by the
persistence of elevated aminotransferase levels and
HCV RNA in serum, but is otherwise generally
asymptomatic. The rate of progression to severe liver
disease is highly variable. Factors that promote clini-
cal progression include alcohol intake, coinfection
with HIV and/or HBV, male sex and older age at
infection [2].
The estimated prevalence of HCV infection world-
wide is 2.2% and active or passive vaccination is not
available to date. Antiviral combination therapy with
a pegylated interferon and ribavirin is usually adminis-
tered only to patients with more advanced and progres-
sive disease [19–21] due to cost, side eﬀects and limited
eﬃcacy, especially in individuals infected with HCV
genotype 1. Therefore, several novel antiviral agents
are currently being evaluated including NS3-4A prote-
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itors and diﬀerent immune therapies [22].3. Association between HCV infection and development of
HCC or other malignancies
Chronic HCV infection is a major risk factor for
HCC development and serological markers of HCV
infection are found in up to 80% of patients with HCC
in some areas of the world [23,24] (Table 1). HCV infec-
tion is estimated to increase the risk for HCC develop-
ment up to 17-fold [3,4]. Host, environmental and
viral factors appear to play an important role in deter-
mining progression of chronic hepatitis C to liver cirrho-
sis and HCC [2]. Some [25–28], but not all clinical
studies [29–32], suggest that the risk of HCC develop-
ment is associated with certain HCV genotypes, particu-
larly genotype 1b. Apart from chronic HCV infection
other risk factors for HCC development are among oth-
ers HBV infection, obesity in men, diabetes mellitus,
heavy alcohol use and hereditary hemochromatosis.
Successful clearance of chronic HCV infection has been
shown to reduce the overall liver-related mortality and
HCC incidence, providing further evidence for a causal
role of HCV in this cancer [33].
Apart from HCC, HCV is also a well-established risk
factor of lymphoproliferative syndromes such as type II
mixed cryoglobulinemia [34] and malignant lymphoma.
Indeed, HCV infection increases the risk of B-cell non-
Hodgkin lymphoma (B-NHL) 2- to 10-fold [35,36]
(Table 1). This association is particularly striking in
southern Europe but much less in northern Europe
and north America [35,36], suggesting that diﬀerences
in HCV prevalence in these geographic regions, in con-
trol populations and in methods of HCV detection may
account for these ﬁndings. The mechanisms underlying
HCV-related lymphoma development, including the
contributing host and viral factors [37] remain to be
identiﬁed. Interestingly, clinical data show a regression
of lymphoma after successful treatment of HCV infec-
tion supporting the concept of HCV infection as a cause
of lymphoma development in humans [38]. HCV infec-
tion has also been linked to the development of intrahe-
patic cholangiocarcinoma (ICC) [39–41]. It remains
unclear, however, whether this association is indepen-
dent from the underlying liver disease/cirrhosis.
Prospective and retrospective cohort studies of
patients with HCV infection have shown the role of
the duration of chronic hepatitis in HCC development
and the link between HCC development and liver cir-
rhosis. These studies demonstrated the sequential occur-
rence of advanced liver ﬁbrosis and the development of
HCC. The incidence of HCC development was esti-
mated to be between 3 and 5%/year in patients with liver
cirrhosis [42,43]. In HCV-infected patients, host andenvironmental factors appear to be more important
than viral factors in determining progression of the liver
disease to cirrhosis and HCC. These factors include:
older age at diagnosis (>55 years: 2- to 4-fold increased
risk) [44,45], duration of infection [30], male sex (2- to 3-
fold increased risk) [46], severity of liver disease at pre-
sentation, co-morbidities such as porphyria cutanea
tarda [47], heavy alcohol intake [3,48–50], diabetes mel-
litus [51,52], steatosis [53,54], obesity [52,55] and coin-
fections, especially with HBV [26,56]. Slightly elevated
serum bilirubin levels, decreased platelet counts and skin
manifestations of liver disease, such as vascular spiders
and/or palmar erythema correlate with the HCC risk
[26,56]. Speciﬁc HLA class II alleles have also been asso-
ciated with progression of chronic hepatitis C to decom-
pensated cirrhosis or HCC. In this context, studies
documented an association between DRB1*1301/2
alleles and an asymptomatic HCV infection [44]. Fur-
ther, an association between the HLA DQ02 allele and
HCC development has been reported [44].4. HCV-induced hepatocarcinogenesis
The mechanisms underlying the progression of HCV
infection to HCC, which usually takes many years or
decades, remain ill-deﬁned [57,58]. Transcriptomics
and proteomics have helped to identify many genetic
and epigenetic alterations associated with HCC clusters.
However, the changes of gene expression identiﬁed in
tumor cells are very heterogeneous, raising the question
whether yet unidentiﬁed, speciﬁc changes at early, pre-
neoplastic stages trigger the transformation process
and whether diﬀerentiated hepatocytes or stem cells
are at the origin of HCC [59,60].
HCV is the only RNA virus with a predominantly
cytoplasmic life cycle [7,8]. All potentially pro-oncogenic
events are therefore likely to be restricted to the cyto-
plasm, suggesting indirect mechanisms of hepatocarci-
nogenesis. While HCV infection leads to chronic
inﬂammation, steatosis, ﬁbrosis and oxidative DNA
damage, several HCV proteins have been shown to have
direct oncogenic eﬀects and to upregulate mitogenesis
[57,61] (Table 2). The accumulation of oxidative stress
and DNA damage in a setting of restricted cell cycle
checkpoint control and/or accelerated cell division, is
thought to compromise gene and chromosome stability
and to form the genomic basis for the malignant trans-
formation (Fig. 1). Indeed, in chronic HCV infection,
changes in mitogen-activated protein kinase (MAPK)
signaling, that regulates both cell metabolism and
growth, are frequently detected [62,63]. Markers of
intracellular oxidative stress have also been found to
be increased in patients with chronic HCV infection
[64,65] as well as HCV core transgenic mice [66,67].
However, direct interactions of the various HCV pro-
Table 2
HCV proteins, their role in the viral life cycle and possible roles in hepatocyte transformation.
HCV proteins Role in viral life cycle Possible roles in hepatocyte transformation (examples)
Core protein Nucleocapsid assembly Insulin resistance/steatosis/oxidative stress
Interference (direct or indirect) with p53, p73, pRb
Interference with host cell signaling
(NF-jB, Raf1/MAPK, Wnt/b-catenin pathway)
Interference with TGF-b signaling
Transcriptional activation of cellular genes
Apoptosis
E1/E2 glycoprotein Virus morphogenesis Interference with PKR activity
Cell entry
p7 Virus assembly, export and infectivity
NS2 Polyprotein processing and viral assembly Apoptosis
NS3 N-terminal domain Serine protease activity Interference with hepatocyte innate response
Interference with NF-KB
Interference with p53
NS3 C-terminal domain Helicase activity
HCV genome replication
NS4A Co-factor of NS4B and NS5A ER stress
NS4B Formation of membranous
web structures ER stress
NS5A Part of the replication complex Interference with protein ubiquitinylation
Inhibition of PKR activity
Oxidative stress
Modulation of transcription of cellular genes and rRNA
Activation of cell signaling pathways (STAT-3, NF-jB etc)
Accumulation of b-catenin by indirect mechanism
NS5B RNA dependent RNA polymerase
B. Bartosch et al. / Journal of Hepatology 51 (2009) 810–820 813teins with host cell factors have also been shown to lead
to changes in cellular signaling cascades involved in reg-
ulation of cell metabolism and division and seem to be
suﬃcient to induce hepatocarcinogenesis [66,68]. Over-
all, it is thought that the synergism between chronic
inﬂammation and direct virus–host cell interactions trig-
gers the malignant transformation of hepatocytes. The
requirement for such a synergism would also explain
the slow ‘multi-step’ transformation process that under-
lies human HCC development. Indeed, a considerable
time lag between HCV infection and the development
of cirrhosis and HCC is common and also explains the
heterogeneity of genetic and epigenetic alterations
observed in diﬀerent HCCs [57,58,69].
In chronic HCV infection, pro-carcinogenic cofactors
are steatosis, oxidative stress and insulin resistance (IR).
Thus chronic hepatitis C shares many similarities with
non-alcoholic fatty liver disease (NAFLD), which may
lead to non-alcoholic steatohepatitis (NASH) and
HCC. In NAFLD, chronic excess of nutrients causes
endoplasmic reticulum (ER) stress and leads to
increased steatosis and IR. These phenomena are intrin-
sically linked, amplify each other and induce inﬂamma-
tion, which in turn favors hepatocarcinogenesis. The
accumulation of unnaturally high levels of fat in the
liver has been known to trigger the recruitment of
inﬂammatory cells and to increase the levels of pro-oxi-
dants. Reactive oxygen species (ROS) act directly on
essential biomolecules and induce hepatotoxicity. ROSalso indirectly activate redox sensitive transcriptional
cascades, which trigger the production of cytotoxic, pro-
inﬂammatory and ﬁbrogenic mediators. Steatosis and
ER/oxidative stress, have both causal roles in the devel-
opment of IR by molecular pathways that are only
beginning to be elucidated [70]. In IR, insulin receptor
substrate (IRS)-induced signaling is frequently downreg-
ulated or blocked by various mechanisms, but the eﬀects
on downstream signaling pathways remain largely unex-
plored. Apart from ER stress and fatty acid metabolites,
IR can also be triggered by peptide mediators and cyto-
kines secreted by adipose tissue and/or the liver. Finally,
IR and oxidative stress aggravate steatosis by stimulat-
ing lipid synthesis, increasing the transfer of fatty acids
from adipose tissue to the liver and inhibiting lipid secre-
tion by interference with mitochondrial function. In
conclusion, a complex interplay between steatosis, ER/
oxidative stress and IR, whose underlying molecular
mechanisms remain largely undeﬁned, can lead to
chronic liver inﬂammation, apoptosis and ﬁbrogenesis
that are central to the development of liver cirrhosis
and HCC in patients with chronic hepatitis C.5. HCV-induced changes in the hepatic glucose and lipid
metabolism
Similar to NAFLD, ER/oxidative stress, steatosis
and IR are involved in the pathogenesis of chronic
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directly induced by HCV (Fig. 1 and Table 2). An
increased prevalence of steatosis and IR has been
observed in patients with HCV infection and has prog-
nostic implications, as it is associated with faster pro-
gression to cirrhosis and HCC as well as with a poorer
response to treatment. In patients infected with HCV
genotypes 1 and 2, steatosis often develops in the con-
text of a pre-existing diabetes, IR or increased body
mass index. By comparison, in patients infected with
HCV genotype 3, steatosis is directly induced by HCV,
because it correlates with the viral load and reverses
with response to antiviral treatment [71]. HCV is
thought to induce steatosis by interfering with lipid
secretion and degradation and by increasing lipid syn-
thesis. The HCV core protein, which localizes to the sur-
face of lipid droplets and mediates viral assembly in
close association with the cellular fatty acid metabolism
[16], as well as some HCV non-structural proteins, have
been shown to interfere with vLDL secretion [72,73].
HCV infection also upregulates lipid synthesis [63],
inhibits fatty acid oxidation [74,75] and increases release
of fatty acids from adipocytes [71]. Overall the eﬀects of
HCV proteins on lipid synthesis, secretion and oxidation
seem to be most pronounced in HCV genotype 3 infec-
tion, but also occur in patients infected with other geno-
types. Besides changes in the lipid metabolism, HCV
core and several non-structural proteins, induce sys-
temic oxidative stress and related signaling by various
mechanisms [76]. With respect to IR, all HCV genotypes
have been shown to interfere with glucose homeostasis,
often at early stages in HCV infection [71]. The mecha-
nism underlying IR and its severity seems again to be
genotype dependent. HCV has been shown to interfere
with insulin signaling by proteasomal degradation of
IRS-1 and -2 either via SOCS proteins or the PI3K/
Akt/mTOR pathway, as well as by IRS-1 inactivation
via transforming growth factor (TGF)-a and PI3K/
Akt [77]. Thus, the initial or early stages of HCV infec-
tion are strongly associated with IR. In contrast, at late
stages of disease and in particular in tumorigenesis,
transformed cells have been shown to require more glu-
cose and to upregulate insulin sensitivity and glucose
uptake [78].6. From liver inﬂammation to liver cancer
The interdependence between steatosis, IR and oxi-
dative stress is important for disease progression in
NAFLD as well as in hepatitis C and induces tissue
damage and inﬂammation with activation of hepatic
stellate cells (HSCs). Activated HSCs become respon-
sive to both proliferative and ﬁbrogenic cytokines
and undergo epithelial to mesenchymal trans-diﬀerenti-
ation (EMT) into contractile myo-ﬁbroblast-like cells,that synthesize extracellular matrix (ECM) compo-
nents, which accumulate over time to form ﬁbrous
scars or ﬁbrosis. Ultimately, regenerating hepatocytes
become enclosed by scar tissue and form nodules that
deﬁne cirrhosis. HSCs are activated by products and
eﬀectors of oxidative stress and growth factors, cyto-
kines, adipokines and chemokines, secreted by hepato-
cytes, Kupﬀer and inﬂammatory cells that inﬁltrate the
liver in response to infection. The cytokine TGF-b, a
potent inhibitor of epithelial cell growth and tumor
suppressor, is a key regulator of EMT and also has
pro-oncogenic functions. Importantly, recent ﬁndings
indicate that TGF-b induces EMT not only in HSCs
but possibly also in hepatocytes [79]. TGF-b signaling
is upregulated in ﬁbrosis in HCV-infected patients
and stimulates ECM deposition and accumulation. IR
may link ﬁbrosis and steatosis, since it stimulates HSCs
to deposit ECM. Several signaling cascades are
involved in ﬁbrogenesis, including SMADs, PI3K-Akt
and various MAPK pathways, such as p38 and JNK.
While SMADs are indispensable for EMT, TGF-b sig-
naling via SMAD interacts with other signaling path-
ways to mediate pro-oncogenic EMT. JNK activation
by the pro-inﬂammatory cytokine interleukin (IL)-1b
can shift TGF-b signaling from tumor suppression to
oncogenesis with increased ﬁbrogenesis, cell motility
and transactivation of cell cycle regulatory genes
[79,80]. Thus, in the context of chronic inﬂammation,
the interplay between ER/oxidative stress, steatosis
and IR induces a pro-oncogenic microenvironment that
results in ﬁbrogenesis and genomic instability. Even
though HCV has been reported to have direct trans-
forming properties, the liver microenvironment is
thought to signiﬁcantly modulate the transformation
process because HCC develops in chronic HCV infec-
tion only over long periods of time.7. Direct oncogenic eﬀects of HCV
Apart from complex interactions among themselves,
HCV proteins interact with a number of host factors
and signaling pathways and thus contribute to the pro-
gression from chronic hepatitis C to liver cirrhosis and
HCC (Table 2). By modulating gene transcription and
translation as well as post-translational events, the
HCV proteins interfere with innate immunity to favor
viral persistence and liver inﬂammation; they alter cell
signaling, apoptosis, membrane physiology and protein
traﬃcking, induce oxidative stress, genomic instability
as well as malignant transformation. Among the HCV
proteins core, NS3, NS4B and NS5A have all been
shown to have transforming potential when transiently
or stably expressed in cell culture, or in transgenic mice
expressing the diﬀerent viral proteins or the HCV poly-
protein [81–84].
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protein that multimerizes, probably in conjunction with
microtubules [85] to form the viral nucleocapsid and to
package the viral RNA genome. It is localized at the
cytoplasmic surface of the ER and on lipid droplets,
and the latter observation is likely related to the induc-
tion of liver steatosis observed in HCV-infected patients
as well as in transgenic mice overexpressing HCV core
[86–88]. Core has also been shown to localize to the
outer membrane of mitochondria [89] and is involved
in changes of apoptosis and lipid metabolism as well
as in malignant transformation. Among many interac-
tions with cellular factors, core has been shown to
induce ROS production via interaction with heat shock
protein Hsp60 [90], and to bind the tumor suppressor
proteins p53 [91,92], p73 [93] and pRb [94]. Core also
inhibits the expression of the cyclin-dependent kinase
(CDK) inhibitor p21/Waf [95]. p21 is a transcriptional
target of p53 and blocks the cyclin/CDK complexes
involved in cell-cycle control and tumor formation. Core
induces activation of the Raf1/MAPK pathway [96,97],
protects cells from serum starvation and growth arrest
and drives cells into proliferation. NF-jB transcription
has been shown to be activated [98–100] and repressed
[101] by HCV core. HCV core has also been shown to
activate the Wnt/b-catenin pathway, which controls cell
proliferation, DNA synthesis and cell-cycle progression
[102]. Furthermore, HCV core variants have been
shown to interact with SMAD3 and to inhibit the
TGF-b pathway [103]. TGF-b signaling not only con-
trols cell proliferation, diﬀerentiation and apoptosis
but also stimulates liver regeneration and ﬁbrogenesis
through its actions on the ECM (see above). TGF-b lev-
els are frequently increased in patients with chronic
HCV infection and correlate with the degree of ﬁbrosis
[104,105]. Finally, HCV core protein associates with cel-
lular membranes [88,106] and lipid vesicles [106], binds
to apolipoprotein II [107,108] and reduces microsomal
triglyceride transfer protein activity [108], resulting in
impaired assembly and secretion of vLDL, steatosis
and oxidative stress. These in vitro ﬁndings are likely
to be relevant for HCV pathogenesis because transgenic
mice expressing HCV core protein also develop steatosis
[108,109] and HCC [67,68].
Overexpression of E2 inhibits eIF2a phosphorylation
by the dsRNA-activated protein kinase (PKR) or the
ER-stress signaling kinase PERK [110,111]. Similarly,
overexpression of NS4A, NS4B, or NS4A-4B has been
reported to induce an ER stress-mediated unfolded pro-
tein response, to reduce ER-to-Golgi traﬃcking, to inhi-
bit protein synthesis, and to cause cytopathic eﬀects
[112–116]. NS2 has been shown to inhibit the cellular
proapoptotic molecule CIDE-B [117] and to downregu-
late transcription [118].
NS3-4A serine protease has been reported to interact
with p53 to repress p21 function, to block activation ofthe transcription factors IRF-3 and NF-jB and to
antagonize the innate antiviral defenses by interfering
with RIG-1, MDA5 and TLR3 mediated signal trans-
duction [119–121]. Indeed, RIG-I inactivation has been
shown to render Huh-7 cells permissive to HCV replica-
tion [122,123].
NS5A has been shown to interact with the geranyl-
geranylated cellular protein FBL2 [124], an F-box motif
containing protein that is probably involved in targeting
cellular proteins of yet unknown identity for ubiquitiny-
lation and degradation. A number of studies suggest
that NS5A is also involved in IFN resistance [8] and
one possible mechanism may be its ability to induce
expression of the type I interferon antagonist IL-8
[125]. In addition, NS5A has been described to contain
an ‘interferon sensitivity determining region’ (ISDR),
that has been described to mediate inhibition of PKR,
an activator of the innate immunity [83,126,127]. The
accumulation of mutations in this region is thought to
correlate with treatment eﬃcacy [128,129]. Importantly,
overexpression of NS5A has been reported to induce a
number of eﬀects in cells, including oxidative stress, acti-
vation of signaling pathways such as STAT-3, PI3K,
and NF-jB and altered transcriptional regulation of
p21 [130–132] and of pRB [133]. Other NS5A interac-
tion partners include apolipoprotein A1, the major pro-
tein found on HDLs, the tumor suppressor p53, Grb-2,
an adaptor protein involved in mitogen signaling,
SRCAP, an adenosine triphosphatase (ATPase) that
activates cellular transcription, karyopherin b3, a pro-
tein involved in nuclear traﬃcking, cyclin-dependent
kinases 1 and 2 and Src-family kinases Fyn, Hck, Lck,
and Lyn [8,134–137]. It has also been reported that
NS5A expression in the context of the HCV polyprotein
results in the inhibition of the transcription factor Fork-
head as well as in the phosphorylation and inactivation
of the GSK-3, leading to accumulation of b-catenin and
stimulation of b-catenin-dependent transcription [138].
Finally, NS5A dependent activation of upstream bind-
ing factor, a Pol I DNA binding transcription factor,
which occurs as a result of up-regulation of both cyclin
D1 and CDK4, leads to enhancement of rRNA tran-
scription activation [139].8. Genetic and epigenetic changes in HCV-induced
hepato-carcinogenesis
HCCs are genetically very heterogeneous tumors.
This is not unexpected, given the number of etiological
factors implicated in its development, the complexity
of hepatocyte physiology and the advanced stage at
which HCCs are usually diagnosed. Genome-wide anal-
ysis of genetic alterations occurring in HCC revealed
two major mechanisms of hepatocarcinogenesis. In the
ﬁrst, genetic alterations are acquired in the context of
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between chronic inﬂammation, IR and steatosis; in the
second, transformation is induced by b-catenin muta-
tions that dysregulate the Wnt pathway [140]. So far,
it has not been possible to correlate chromosome insta-
bility with a consistent pattern of proto-oncogene acti-
vation in HCC, but several growth factor signaling
pathways are frequently aﬀected, including insulin-
growth factor (IGF)-, hepatocyte growth factor-, Wnt-
, TGF-a/EGF- and TGF-b-signaling [58,141]. The inter-
play between these pathways and their respective roles
and contributions to HCC development remain to be
elucidated, however. One of the most commonly aﬀected
pathways involved in cell cycle check control is the p53
pathway, that limits cell survival and proliferation in
response to telomere shortening and oncogene activa-
tion in order to ensure genome integrity. Loss of p53
by e.g. deletion, mutation, degradation or direct inhibi-
tion during progression of chronic hepatitis C to cirrho-
sis likely results in proliferation of hepatocytes with
shortened telomeres or chromosomal damage and to
predispose to hepatocarcinogenesis. Indeed, p21 expres-
sion, a downstream target of p53 that blocks cell entry
into the S phase, is increased in cirrhosis when presum-
ably signiﬁcant numbers of hepatocytes with genome
damage have accumulated, but is lost in premalignant
liver lesions and HCC [142]. Besides p53, the retinoblas-
toma (Rb) pathway is another major checkpoint that
limits cell proliferation in response to DNA damage,
telomere shortening and oncogene activation. In human
HCC, the Rb pathway is defective in more than 80% of
cases [143]. Moreover, gankyrin, an inhibitor of p53 and
Rb check point function is overexpressed in the vast
majority of HCCs [144]. Expression of IGF-2 is frequent
and thought to be an early event in hepatocarcinogene-
sis, present in more than 60% of dysplastic nodules and
HCC [145]. IGF-2 receptor impairs cell proliferation by
promoting degradation of the IGF-2 mitogen and by
activation of TGF-b signaling [146].
b-catenin pathway activation is very common in
hepatocarcinogenesis and detectable in more than 50%
of HCCs. It can directly induce hepatocyte transforma-
tion without the need for multiple genetic/epigenetic
alterations [147]. b-catenin activation is mainly induced
by b-catenin gene mutations and/or Wnt signaling path-
way alterations [143]. Wnt/frizzled/b-catenin signaling is
mediated by a complex interaction between a Wnt
ligand (Wnt) and a Frizzled receptor (Fzd), mostly in
cooperation with the low density lipoprotein receptor
(LDLR)-related proteins LRP-5 or -6. Normally, the
Wnt/b-catenin pathway is involved in cell growth and
proliferation as well as developmental control and cell
adhesion. Cellular levels of b-catenin are tightly regu-
lated by proteasome-dependent degradation, which is
in turn controlled by the activity of the APC and Axin1
proteins, and the glycogen synthase kinase (GSK)-3b. Arecent report indicates that Fzd-7, which stabilizes and
activates b-catenin [148], is overexpressed in more than
90% of HCCs and in around 75% of the peritumor-
ous/precancerous liver tissue.
In addition to the dysregulation of the above path-
ways, HCV infection has been shown to induce or cor-
relate with epigenetic changes that are likely to
contribute to hepatocarcinogenesis. HCV-induced
ROS have been shown to activate histone deacetylase
in a fashion similar to hydrogen peroxide and to cause
hypoacetylation of histones [149]. Hypomethylation of
the IGF-2 locus in hepatitis C cirrhosis has been shown
to predict HCC development [150]. Another study
reported the hypermethylation of p16, p15, p14, pRB
and the PTEN promoters in patients with sustained viral
response in comparison to non-responders [151].
Finally, increased hTERT DNA levels have been found
to predict HCC development [152].9. Conclusions
Our current view is that the mechanism of HCV-
induced HCC is multifactorial. However, because of
the lack of adequate models, it has been diﬃcult to dem-
onstrate the speciﬁc roles of HCV proteins and the liver
micro environment in the malignant transformation of
hepatocytes. To identify and characterize these mecha-
nisms, primary human hepatocyte cultures supporting
chronic HCV infection would be most useful to examine
the accumulation of transforming events, leading to the
selection of transformed cells after several cell passages.
An immunocompetent animal model, susceptible to
chronic HCV infection, would be important to analyze
not only the diﬀerent viral proteins, but also the liver
microenvironment involved in HCC development
(including IR, steatosis, oxidative stress, cytokine
expression in response to HCV expression, liver regener-
ation, ﬁbrosis, etc.). The recent discovery of cellular co-
receptors required for virus-entry and the better under-
standing to the molecular biology of HCV replication
should open new avenues to address these important
questions.Acknowledgment
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